MarketScreener Homepage > Equities > Swiss Exchange > Lonza Group AG LONN CH0013841017

Report

Delayed Swiss Exchange - 01/27 03:02:21 am
589.4	CHF		-1.77%

01:53a

LONZA : Books Higher 2020 Earnings; Increases Dividend

01:22a

LONZA : FY20 Profit Rises On Positive Pharma Biotech, Nutrition Performance

01:06a

LONZA : Reports Strong 2020 Performance, Driven By Sales Growth in Pharma and Biotech Business

Summary

Quotes 5-day view Delayed Quote.

Delayed Swiss Exchange

01/21/2021	01/22/2021	01/25/2021	01/26/2021	01/27/2021	Date
595.2(c)	599.2(c)	607.4(c)	600(c)	589.4	Last
165 053	192 630	246 639	224 816	8 494	Volume
+0.30%	+0.67%	+1.37%	-1.22%	-1.77%	Change

More quotes

Financials

Sales 2020	6 161 M 6 944 M 6 944 M
Net income 2020	844 M 952 M 952 M
Net Debt 2020	2 915 M 3 285 M 3 285 M
P/E ratio 2020	51,9x
Yield 2020	0,49%

Sales 2021	6 546 M 7 378 M 7 378 M
Net income 2021	969 M 1 092 M 1 092 M
Net Debt 2021	2 448 M 2 759 M 2 759 M
P/E ratio 2021	45,1x
Yield 2021	0,53%

Capitalization	44 573 M 50 227 M 50 239 M
EV / Sales 2020	7,71x
EV / Sales 2021	7,18x
Nbr of Employees	15 913
Free-Float	99,6%

More Financials

Company

Lonza Group is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals and nutritional ingredients (70.4%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, nutritional ingredients, etc. In addition, the group offers dosage solutions for...

Sector

Biotechnology & Medical Research

Calendar

01/27

Earnings Release

More about the company

Notations Surperformance© of Lonza Group AG

Trading Rating :

Investor Rating :

More Ratings

All news about LONZA GROUP AG

01:53a	LONZA : Books Higher 2020 Earnings; Increases Dividend	DJ
01:22a	LONZA : FY20 Profit Rises On Positive Pharma Biotech, Nutrition Performance	MT
01:06a	LONZA : Reports Strong 2020 Performance, Driven By Sales Growth in Pharma and Bi..	PU
01/25	Lonza Partner Moderna's COVID-19 Shot Proves Effective Against New Variants	MT
01/24	MARKET CHATTER : Lonza's $4 Billion Specialty Ingredients Business Attracts Bid ..	MT
01/20	LONZA : NextPharma Set to Acquire Two Lonza Sites Specialized in Lipid Oral Dosa..	AQ
01/19	LONZA : Aruvant chooses Lonza to Manufacture ARU-1801 a Potentially curative Tre..	AQ
01/19	LONZA : Signs Agreement to Sell Two Sites to NextPharma	DJ
01/19	LONZA : to Divest Two Lipid Oral Dosage Producing Sites in France, UK, to NextPh..	MT
01/18	LONZA : to Manufacture Sickle Cell Disease Therapy for Aruvant Sciences	MT
01/18	LONZA : Aruvant chooses Lonza to Manufacture ARU-1801, a Potentially curative Tr..	PU
01/17	LONZA : Partner Moderna to Deliver 7.5 Million COVID-19 Shots to Switzerland By ..	MT
01/15	GLOBAL MARKETS LIVE: Citigroup, Wells Fargo, SAP…
01/15	LONZA : Invitation to Lonza's Full-Year Results 2020 Conference Call and Webcast	PU
01/14	Lonza Group Awaits Swiss Regulator Licensing For Moderna Vaccine Ingredients	MT

More news

News in other languages on LONZA GROUP AG

03:05a	FMI, Super-cycle et Microsoft au programme
02:38a	Lonza steigert Gewinn und treibt Verkauf des Chemiegeschäfts voran
02:27a	EN DIRECT DES MARCHES : LVMH, Microsoft, Sartorius, Somfy, Solutions 30, Sanofi,..
02:14a	STOCK MARKET PARIS : Les valeurs à suivre à Paris et en Europe
02:08a	Lonza a soigné croissance et rentabilité en 2020

More news

Analyst Recommendations on LONZA GROUP AG

01/08	LONZA : Morgan Stanley Lowers Price Target on Lonza, Maintains Overweight/In-Lin..	MT
01/08	LONZA : Jefferies Lifts Price Target on Lonza, Maintains Buy Recommendation	MT
2020	Day by Day Lifts Price Target on Lonza, Maintains Buy Recommendation	MT

More recommendations

Stock Trading Strategies

	LONZA GROUP AG - 2020
The stock is approaching a major resistance level

BUY

More Stock Trading Analysis

Provided by Scoopnest.com

Analysis

Moderna files for U.S. vaccine authorization, will seek EU nod